NASDAQ:BLRX - BioLineRx Ltd.
$0.37
 $-0.01
-1.34%
4:00PM EDT
2019-04-18
BioLine RX Ltd is an Israel-based company engaged in the development of therapeutics, from preclinical-stage development to advanced clinical trials, for a range of medical needs. Its clinical therapeutic candidates under development consist of BL-1020 that is in Phase II/III clinical trials to improve cognitive function in schizophrenia patients; BL-1040, which is under pivotal CE-Mark registration trial for the prevention of cardiac remodeling following an acute myocardial infarction; BL-5010, which has completed Phase I/II clinical trials for non-surgical removal of skin lesions; BL-1021 that has completed Phase Ia clinical trial for the treatment of neuropathic pain or pain that results from damage to nerve fibers, and BL-7040, a synthetic oligonucleotide, which is in Phase II clinical trial for the treatment of inflammatory bowel disease. The Company also has 11 pre-clinical stage development products for various indications. Read more at  reuters.com
sector:  health care
industry:  biotechnology
the data below are updated and published after 9pm EDT each trading day
  BLRX     avg for
industry  
  avg for
sector  
42 stocks weight:  -1000. 00 M 199. 07   233. 87  
42 stocks rank:  4. 45 K 1. 43 K 1. 06 K
# analyst opinions:  4. 00   14. 48   14. 09  

quick ratio:  4. 66   5. 29   1. 92  
current ratio:  4. 74   5. 64   2. 40  

target price low:  0. 28   84. 50   115. 74  
target price avg:  0. 30   110. 73   137. 39  
target price high:  0. 64   136. 41   157. 80  
1-yr high:  1. 45   114. 11   138. 85  
last close:  0. 38   87. 56   116. 78  
50-day avg:  0. 42   95. 43   123. 53  
200-day avg:  0. 71   94. 13   121. 20  
1-yr low:  0. 38   72. 67   98. 41  
volume:  220. 67 K 2. 43 M 4. 85 M
50-day avg volume:  1. 18 M 2. 72 M 4. 97 M
200-day avg volume:  992. 86 K 2. 90 M 4. 58 M

1-day return:  0. 00 % -0. 40 % 0. 07 %
this week return:  -7. 32 % -5. 72 % -4. 11 %
12-wk return:  -36. 67 % 1. 78 % -0. 04 %
52-wk return:  -51. 55 % 10. 81 % 14. 09 %

enterprise value (EV):  37. 63 M 51. 19 B 117. 96 B
market cap:  55. 60 M 43. 00 B 104. 52 B
EBITDA:  -25. 15 M 4. 45 B 8. 01 B
enterprise multiple (EV/EBITDA):  -1. 50   4. 34   13. 27  
total debt:  8. 73 M 12. 22 B 16. 66 B
debt/equity:  21. 13   46. 86   89. 46  
net income (common):  -22. 96 M 2. 20 B 4. 21 B

shares outstanding:  108. 08 M 570. 91 M 1. 24 B
shares:  113. 56 M 571. 02 M 1. 23 B
shares short:  714. 36 K 9. 93 M 16. 79 M
shares short prior month:  1. 15 M 9. 96 M 16. 58 M
short ratio:  0. 69   5. 31   3. 30  
total cash/share:  0. 21   11. 13   9. 30  
total cash:  30. 15 M 6. 70 B 7. 10 B
free cash flow:  -25. 13 M 3. 58 B 4. 74 B
operating cash flow:  -24. 19 M 4. 14 B 6. 32 B

book value:  0. 36   12. 76   26. 84  
price/book:  1. 06   3. 08   -1. 74  
operating margins:  0. 00 % -721. 97 % -88. 82 %
EBITDA margins:  0. 00 % 10. 94 % 22. 54 %
profit margins:  0. 00 % 7. 81 % 10. 60 %
gross margins:  0. 00 % 37. 02 % 55. 68 %

1-yr max volatility:  -39. 73 % --- ---
1-yr mean volatility:  -0. 20 % 0. 03 % 0. 04 %

1-yr EPS:  -0. 21   2. 39   4. 08  
forward EPS:  -0. 12   3. 97   7. 14  
P/E:  -1. 80   13. 59   22. 83  
forward P/E:  -3. 46   -20. 05   14. 49  
PE/G:  0. 06   -1. 46   1. 68  
growth:  -30. 12 % 126. 81 % 29. 29 %
earnings high:  -0. 05   1. 02   1. 63  
earnings avg:  -0. 09   0. 76   1. 51  
earnings low:  -0. 19   0. 47   1. 39  
revenue high:  150. 00 K 2. 68 B 10. 71 B
revenue avg:  40. 00 K 2. 59 B 10. 49 B
revenue low:  -0. 00   2. 49 B 10. 25 B
return on assets:  -27. 31 % -2. 80 % 5. 29 %
return on equity:  -48. 75 % -18. 52 % 7. 38 %

beta (1yr vs S&P500):  0. 55   1. 24   0. 93  
sharpe (1yr):  -0. 66   0. 29   0. 60  

held % insiders:  3. 46 % 6. 38 % 3. 38 %
held % institutions:  27. 13 % 78. 60 % 68. 65 %

Research more with google or yahoo!
the data below are updated and published after 9pm EDT each trading day

2019-04-19 : BLRX
.    + 0.405 =         0.405 :: INITIAL WEIGHT
.   + 34.412 =        34.818 :: spline projection addition
.    x 1.432 =         49.86 :: industry recommendation factor
.    x 0.997 =        49.724 :: return on assets factor
.    x 0.995 =        49.482 :: return on equity factor
.     x 2.84 =       140.534 :: current ratio factor
.    x 1.128 =       158.556 :: quick ratio factor
.    x 1.618 =       256.497 :: short ratio factor
.    x 2.011 =       515.702 :: price-to-book factor
.    x 1.205 =       621.199 :: debt-to-equity factor
.    x 2.147 =      1333.408 :: P/E weight
.    x 2.022 =      2696.487 :: PE/G factor
.    x 1.548 =      4175.249 :: beta factor
.    x 0.656 =      2739.009 :: sharpe factor
.    x 0.947 =      2595.031 :: target low factor
.    x 0.919 =      2383.988 :: target mean factor
.    x 1.082 =      2579.899 :: target high factor
.    x 1.312 =       3383.92 :: industry 2-weeks return factor
.    x 0.957 =      3239.636 :: "drift" penalty 3 days ago
.    x 0.932 =      3018.538 :: "drift" penalty 4 days ago
.    x 0.918 =      2771.986 :: overall "drift" factor
.    x 0.998 =      2765.693 :: largest single-day jump factor
.     x 0.06 =       164.625 :: low price factor
.      x 1.0 =       164.598 :: factor hist industry gain for week 15
.   cubeRoot =          5.48 :: reduced to standardize
.   - 22.872 =         0.749 :: add/subtract for performance
. -999999999.999 zero/no returns for 20 days out of the past 42x trading days
.                  -999999999.999 :: FINAL WEIGHT for NASDAQ:BLRX


 


News feed RSS items generated from finance.google.com

News feed formatting by feed2js.org